Computationally restoring the potency of a clinical antibody against SARS-CoV-2 Omicron subvariants

• Published in: bioRxiv
• Main Authors: Desautels, Thomas A, Arrildt, Kathryn T, Zemla, Adam T, Lau, Edmond Y, Zhu, Fangqiang, Ricci, Dante, Cronin, Stephanie, Zost, Seth J, Binshtein, Elad, Scheaffer, Suzanne M, Dadonaite, Bernadeta, Petersen, Brenden K, Engdahl, Taylor B, Chen, Elaine, Handal, Laura S, Hall, Lynn, Goforth, John W, Vashchenko, Denis, Nguyen, Sam, Weilhammer, Dina R, Lo, Jacky Kai-Yin, Rubinfeld, Bonnee, Saada, Edwin A, Weisenberger, Tracy, Lee, Tek-Hyung, Whitener, Bradley, Case, James B, Ladd, Alexander, Silva, Mary S, Haluska, Rebecca M, Grzesiak, Emilia A, Earnhart, Christopher G, Hopkins, Svetlana, Bates, Thomas W, Thackray, Larissa B, Segelke, Brent W, Lillo, Antonietta Maria, Sundaram, Shivshankar, Bloom, Jesse, Diamond, Michael S, Crowe, Jr, James E, Carnahan, Robert H, Faissol, Daniel M
• Format: Journal Article Paper
• Language: English
• Published: United States Cold Spring Harbor Laboratory Press 24.04.2023; Cold Spring Harbor Laboratory
• Edition: 1.2
• Subjects: Antibodies; Bioinformatics; Biotechnology; Computer applications; COVID-19; Laboratories; Microbiology; Monoclonal antibodies; Severe acute respiratory syndrome coronavirus 2; Strains (organisms)

The COVID-19 pandemic underscored the promise of monoclonal antibody-based prophylactic and therapeutic drugs , but also revealed how quickly viral escape can curtail effective options . With the emergence of the SARS-CoV-2 Omicron variant in late 2021, many clinically used antibody drug products lo...